Xeris Pharmaceuticals (XERS) AI Stock Analysis

• Market Cap: $689.65M
• Dividend Yield: N/A
• Average Volume (3M): 3.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.25
• Revenue Growth: 23.89%
• EPS Growth: 16.86%
• Country: US
• Employees: 394
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 153,940,140
• 10 Day Avg. Volume: 2,116,306
• 30 Day Avg. Volume: 3,287,282
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 4.24
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.10
• Price Target Upside: 29.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Xeris Biopharma's stock score is influenced by strong revenue growth and positive earnings call sentiment, but weighed down by financial instability and negative cash flows. Although the technical analysis presents a mixed outlook, positive guidance for 2025 and product performance are promising. The stock's valuation reflects both its growth potential and financial challenges.

Positive Factors

Earnings

Xeris reported 4Q24 financials with total net product revenues of $57.0M, representing ~34% Y/Y growth and marking the 13th consecutive quarter of >20% growth.

Guidance

Xeris's first-time 2025 guidance for $255-275M revenue was a surprising 11% above estimates and up 30% YoY at the midpoint.

Valuation

XERS stock is materially undervaluing the business at just 2.7x EV/REV, which is considered too cheap given its growth.

Negative Factors

Partnerships

Amgen terminated their XeriJect license agreement with Xeris, which might weigh on the stock incrementally.

Xeris Pharmaceuticals Business Overview & Revenue Model

Company Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

How the Company Makes Money

Xeris Pharmaceuticals generates revenue through the sale of its pharmaceutical products, which include ready-to-use injectables for treating acute and chronic medical conditions. Key revenue streams for the company include sales of its flagship products like Gvoke, a glucagon injection used to treat severe hypoglycemia. Xeris also earns revenue through partnerships and collaborations with other pharmaceutical companies, leveraging its proprietary formulation technologies to develop new therapeutics. Additionally, the company may receive milestone payments and royalties from collaborative agreements, contributing to its overall earnings.

Xeris Pharmaceuticals Financial Statement Overview

Summary

Xeris Pharmaceuticals exhibits strong revenue growth but faces profitability and financial stability challenges. The income statement shows improving but still negative margins, while the balance sheet reveals high leverage risk due to negative equity. Cash flow improvements are evident, yet the company remains reliant on external funding.

Income Statement

Xeris Pharmaceuticals has shown a consistent increase in revenue over the years, with a revenue growth rate of 23.89% from 2023 to TTM 2024. However, the company is still operating at a net loss with a negative net profit margin of -27.00% and a negative EBIT margin of -16.57%. Gross profit margin remains relatively strong at 83.88%, indicating effective cost management in production. The EBITDA margin is improving but remains negative, showing progress yet still indicating the need for profitability improvements.

Balance Sheet

The company's balance sheet indicates financial instability with a negative stockholders' equity of -$29.62 million, showing liabilities exceed assets. The debt-to-equity ratio is not meaningful due to negative equity, suggesting high leverage risk. Although the equity ratio is negative, some improvement is noted in the total liabilities management compared to previous years. Nonetheless, the financial stability remains a concern.

Cash Flow

Xeris Pharmaceuticals' cash flow shows signs of strain with a negative free cash flow of -$39.60 million in TTM 2024, although there is a notable 19.65% improvement in operating cash flow from 2023. The free cash flow to net income ratio is slightly improving but still negative, indicating challenges in turning profits into cash flow. Financing activities appear strong, hinting at external funding support for operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
203.07M	163.91M	110.25M	110.25M	49.59M
	Gross Profit
166.24M	135.27M	87.61M	87.61M	36.27M
	EBIT
-33.65M	-44.01M	-81.94M	-81.94M	-115.16M
	EBITDA
-13.99M	-23.73M	-69.31M	-113.67M	-80.08M
	Net Income Common Stockholders
-54.84M	-62.26M	-94.66M	-94.66M	-122.72M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
71.62M	72.45M	121.97M	121.97M	102.43M
	Total Assets
323.06M	322.60M	344.52M	344.52M	304.36M
	Total Debt
271.45M	229.19M	198.06M	198.06M	88.07M
	Net Debt
199.83M	161.74M	76.09M	76.09M	20.80M
	Total Liabilities
352.68M	329.38M	299.33M	299.33M	209.13M
	Stockholders Equity
-29.61M	-6.78M	45.19M	45.19M	95.23M
Cash Flow		Free Cash Flow
-37.85M	-49.29M	-103.42M	-103.42M	-96.62M
	Operating Cash Flow
-36.98M	-47.02M	-102.89M	-102.89M	-95.53M
	Investing Cash Flow
4.88M	-6.00M	34.46M	34.46M	97.96M
	Financing Cash Flow
36.17M	-1.61M	127.47M	127.47M	27.25M

Xeris Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.71
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Positive. The current price of 4.71 is above the 20-day moving average (MA) of 4.29, above the 50-day MA of 4.52, and above the 200-day MA of 3.43, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 51.20 is Neutral, neither overbought nor oversold. The STOCH value of 85.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XERS.

Xeris Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XERS	52 Neutral	$689.65M	―	222.83%	―	23.89%	16.86%
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
ABCL	49 Neutral	$741.99M	―	-14.75%	―	-24.17%	-9.24%
ZYME	48 Neutral	$903.50M	―	-30.54%	―	0.38%	6.94%
NRIX	47 Neutral	$850.79M	―	-64.16%	―	-30.25%	-5.92%
PRAX	42 Neutral	$758.94M	―	-70.98%	―	249.53%	56.59%
XNCR	41 Neutral	$772.71M	―	-34.74%	―	-36.72%	-64.37%

Xeris Pharmaceuticals Corporate Events

Xeris Pharmaceuticals Announces Board Changes with New Appointment

On March 28, 2025, Xeris Biopharma Holdings announced significant changes to its board of directors. Ricki Fairley resigned due to other commitments, and John Schmid decided not to seek re-election at the 2025 Annual Meeting, leading to a reduction in board size to eight members. James Brady was appointed as a new director, bringing extensive experience from his previous roles at AstraZeneca, including as CFO of MedImmune. His appointment is expected to enhance the board’s expertise as Xeris continues to innovate and expand its market presence.

Xeris Pharmaceuticals Appoints New Chief Medical Officer

On February 24, 2025, Xeris Biopharma announced the retirement of Ken Johnson as Senior Vice President, Global Development and Medical Affairs, effective April 1, 2025, and the appointment of Dr. Anh Nguyen as Chief Medical Officer, effective immediately. Dr. Nguyen, who brings extensive clinical and leadership experience, will lead the strategic direction for Xeris’ medical and regulatory functions, coinciding with the company’s Phase 3 development of XP-8121 and efforts to expand its commercial portfolio. This leadership transition is expected to ensure continuity and drive future growth, with Mr. Johnson assisting in the transition process.